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Abstract 
Biopharmaceuticals manufacturing is a critical component of the modern healthcare system, with 
emerging new treatments composed of increasingly complex biomolecules offering solutions to 
chronic and debilitating disorders. While this sector continues to grow, it strongly exhibits “boom-to-
bust” performance which threatens its long-term viability.  Future trends within the industry indicate 
a shift towards continuous production systems using single use technologies that raises 
sustainability issues, yet research in this area is sparse and lacks consideration of the complex 
interactions between environmental, social and economic concerns.  The authors outline a 
sustainability-focused vision and propose opportunities for research to aid the development of a 
more integrated approach that would enhance the sustainability of the industry. 
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1. Introduction 
Biopharmaceuticals, pharmaceutical treatments produced from biological sources, are an important 
and evolving component of the modern healthcare system. Table 1 details a variety of biologically 
sourced pharmaceuticals and their therapeutic indications. 
The first biopharmaceutical treatments can be considered to have developed in the late 19th century, 
with the development of the first vaccines and the proliferation of safe, repeatable blood 
transfusions. The early 20th century then saw the discovery and application of products such as 
insulin, derived from animal sources (and with concomitant risk of adverse allergic reaction to 
treatment), and penicillin, the industrial scale production of which was developed during the second 
world war. A paradigm shift occurred in 1973 with the discovery of recombinant DNA technology by 
Cohen and Boyer, and the fruits of this discovery were realised in 1982, with the regulatory approval 
of recombinant human insulin (Humulin: Eli Lilly & Co, 1982) produced by the genetic engineering of 
E. coli. The ensuing decades have seen the expanded application of recombinant DNA technology to 
develop treatments for a wide variety of conditions, many of which are chronic, debilitating 
disorders with significant impacts on quality of life and life expectancy. The 21st century has brought 
about the commercial approval by the US Food & Drug Administration (FDA) of the first gene 
therapy (Luxturna: Spark Therapeutics, 2017) treating congenital blindness. Successful 
commercialisation of gene therapy represents another paradigm shift in biopharmaceutical 
development, with the prospect of advanced treatments for a large variety of disorders such as 
haemophilia and mucopolysaccharidosis providing therapeutic benefit ( favourable response to 
treatment) with a single dose, in comparison to the prolonged use required for contemporary 
treatments.  
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Table 1: Examples of biologically derived pharmaceutical products 
Era Description Examples Therapeutic Indications 
19th Century – 
Present 
“Conventional” 
biotech products 
Isolated from 
animals or humans 
Blood and blood 
components e.g. blood 
plasma 
  
Blood transfusions 
Stem cell therapies e.g. 
bone marrow transplants 
Leukaemia  
Immunoglobulins Inducing immunity for 
diseases such as tetanus 
following exposure or in 
high-risk individuals 
19th Century – 
Present 
Vaccines 
Provides immunity 
to certain diseases 
Inactivated 
Attenuated 
Toxoid 
Subunit 
Conjugate 
Measles 
Influenza 
Tetanus 
Human papilloma virus 
Hepatitis 
1982 – Present Recombinant 
biopharmaceuticals 
Produced using 
recombinant DNA 
technologies 
Blood factors e.g. Factor 
VIII and Factor IX 
Haemophilia 
Growth factors e.g. human 
growth hormone, 
gonadotrophins 
Growth hormone 
deficiencies 
Breast cancer 
Prostate cancer 
Endometriosis 
Cytokines e.g. interferons, Anaemia 
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Era Description Examples Therapeutic Indications 
interleukins, erythropoietin Bone cancer 
Hepatitis 
Multiple sclerosis 
Enzyme replacement 
therapies 
Lysosomal storage 
disorders e.g. 
mucopolysaccharidosis 
Monoclonal antibodies Cancers 
Autoimmune disorders 
2017 – Present Gene Therapies 
Introduction of 
foreign nucleic acid 
into cells to induce 
therapeutic effects 
Somatic cell gene therapy Haemophilia 
Congenital blindness 
Leukaemia 
 
 
Biopharmaceutical drugs may be categorised based on their source and therapeutic indication, as 
described in Table 1, or based on other factors. Table 2 describes three categories of 
biopharmaceuticals. 
 
Table 2: Terms used to describe treatments 
Type Description Examples 
Blockbuster Drug with revenues exceeding $1 billion in a given year. Humira 
Enbrel 
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Type Description Examples 
Remicade 
Rituxan 
Biosimilar Similar biotherapeutic products, or biosimilars, are drugs 
which are “similar” to existing products in terms of 
therapeutic efficacy (the benefit to the patient from the 
treatment), safety (avoidance of adverse effects) and 
structure. Due to the immensely complex nature of biologic 
molecules, it is prohibitively expensive and scientifically 
difficult to characterise molecules. Therefore, development 
of similar biotherapeutic products to established drugs upon 
patent expiration relies on proving equivalency of 
therapeutic benefit, manufacturing process and safety. The 
result are molecules which are not identical to established 
drugs, but exhibit similar therapeutic benefits and safety as 
established drugs. 
Inflectra 
Ixifi 
Amjevita 
Mvasi 
Orphan Orphan drugs are developed for treatment of conditions 
with small patient populations, defined by the European 
Medical Agency (EMA) as being: life-threatening or 
chronically debilitating; having a prevalence of less than 5 in 
10,000; and, having a lack of treatments delivering 
significant benefit to patients. Regulatory agencies offer 
market exclusivity, tax incentives and/or other financial 
incentives to promote orphan drug development, as 
otherwise it would be prohibitively expensive to do so. 
Revlimid 
Rituxan 
Soliris 
Pomalyst 
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In this review, a thorough examination of the biopharmaceuticals manufacturing industry is 
conducted from a sustainability viewpoint. First, the economic and technological state -of-the-art of 
biopharmaceuticals manufacture is detailed. Identification of the key trends in the industry is 
subsequently explored, namely the pursuit of integrated, continuous manufacturing utilising 
perfusion cell cultures and continuous downstream processing, along with the proliferation of single 
use technology and the advent of new modalities of biopharmaceuticals such as gene therapies. The 
established research in the area of sustainability applied to the biopharmaceuticals manufacturing 
industry is then assessed, and opportunities for further research highlighted. Finally, a vision of a 
sustainability-focused biopharmaceuticals manufacturing industry is outlined.  
 
 
 
 
2. Economic and technological state-of-the art of biopharmaceutical manufacture 
2.1 The biopharmaceutical industry through an economic lens 
The manufacture of substances of therapeutic value from biological sources has evolved since the 
regulatory approval in 1982 of recombinant human insulin (Humulin; Eli Lilly & Company)  to a 
behemoth industry almost four decades later, projected to be worth $445 billion by 2019 (Deloitte, 
2016). Despite a lag in regulatory approvals following the initial breakthrough by Humulin, there has 
been a near-constant rate of drug approvals since 1995, with 45 new substances approved in the 
period 2010-2014 (Walsh, 2014) and a near-record 56 approvals by FDA in 2017 (DeFrancesco, 
2018). That year also saw the FDA approval of the first gene therapy (Luxturna: Spark Therapeutics, 
2017) for congenital blindness, a significant milestone (DeFrancesco, 2018). A significant portion of 
these approvals were for orphan drugs, which, due to their small patient populations, can require 
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significant compensatory pricing to recoup research and development costs (Love et al., 2013). In 
addition, biosimilars are now achieving regulatory approval, providing alternatives to established 
blockbusters. 28 biosimilars had been approved in Europe as of June 2017 (Moorkens et al ., 2017) 
and it is anticipated that biosimilars will earn a market value of up to $35 billion by 2020 (Deloitte, 
2016), providing potential savings of up to $100 billion (Moorkens et al. 2017).  With reports of as 
many as 671 potential first-in-class drugs in development pipelines (PhRMA, 2018), many of which 
exist in the gene therapy and orphan spaces, the biopharmaceutical sector appears se t to continue 
to grow as more and more innovative treatments gain regulatory approval.  
The biopharmaceutical industry is not without its risks, however. While drug development pipelines 
appear healthy, the cost of bringing a drug to market continues to rise, now exceeding $2.5 billion 
(pre-approval cost estimate; DiMasi et al., 2016). This contributes greatly to the exorbitant pricing of 
biopharmaceuticals with the cost of actual drug manufacture estimated to be as low as 5% of total 
price (Love et al., 2013). Indeed, biopharmaceuticals are estimated to cost on average $45 per day in 
comparison to $2 a day for small-molecule treatments (Walsh, 2014). Competition from biosimilars 
may drive a decline in price disparity of circa 10-30%, though this still falls short of established 
pricing for small-molecule products (Love et al., 2013). The advent of gene therapy requires 
additional considerations due to the nature of treatment. Gene therapies may offer a “cure”, that is, 
a single treatment may provide clinical benefit for long periods, potentially indefinitely (Brennan and 
Wilson, 2013). As a result, where conventional treatments provide steady income streams for 
biopharmaceutical manufacturers over a patient’s lifetime, gene therapies may require a single 
payment for a lifetime benefit (Brennan and Wilson, 2013). In order to recoup the huge clinical 
development costs, prices in excess of $1 million upfront could be warranted, risking public outcry 
(Brennan and Wilson, 2013). While this may be ameliorated by utilising novel policies including 
performance related pricing and annual payments (Brennan and Wilson, 2013), a historical 
assessment of the financial performance of biotechnology companies (Thakor et al ., 2017) with this 
conundrum in mind proves foreboding. As evidenced by Thakor et al., biotechnology companies 
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have consistently underperformed in the market and shown propensity for unprofitability (Thakor et 
al., 2017). A large part of this is a result of scientific challenges in drug development, multiple 
contenders for treatment of the same illness facing approval at once, and the falling-off of financing 
during periods of economic downturn (Thakor et al ., 2017). Should gene therapies lead to large 
initial uptake and subsequent decline, investors may baulk at the risk of a “boom-and-bust” 
scenario, of the sort that the industry has historically demonstrated, and financing of future 
treatments may be critically compromised. 
 
 
 
2.2 Technological considerations for biopharmaceuticals manufacturing 
2.2.1 Biopharmaceutical drug structure 
In contrast to chemically synthesised drugs, the structures of which are known and whose molecular 
mass does not often exceed about one kilodalton (kDa), biopharmaceutical drugs are often complex 
proteins, with molecular masses orders of magnitude greater. As a result of this molecular size and 
complexity, additional considerations are required of biopharmaceuticals compared to chemically 
synthesised drugs, including immunogenicity (provocation of immune response on introduction to 
body), folding and modification of molecules, and sensitivity of molecules to temperature, pH, 
enzymatic degradation and other conditions encountered during manufacturing.  
The simplest biopharmaceuticals are proteins such as insulin (molecular weight about 5 kDa), a 
hormone which regulates metabolism in the human body, and somatotropin, or human growth 
hormone (molecular weight about 22 kDa), which stimulates cell reproduction, regeneration and 
growth in the human body. Such (relatively) simple proteins are biologically active in the human 
body following protein biosynthesis in the host cell  without need for further chemical modification 
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following translation of messenger RNA in the ribosome. Simple proteins such as these composed 
approximately 7.5% (48 of 640) of all EMA approved drugs in 2012 (Kyriakopoulos and Kontoravdi, 
2013).  
Increasing complexity of biopharmaceutical proteins is due to the requirements of post-translational 
modification by the host cell following the protein’s manufacture in the ribosome of the host cell. 
Post-translational modification refers to the modification, often by enzymatic reactions, of proteins 
following translation of messenger RNA in the ribosome to generate the initial polypeptide chain, 
and is present in many biopharmaceutical proteins in the form of glycosylation, which is the 
modification of the protein by addition of a carbohydrate molecule to the protein structure. 
Glycosylation results in positive consequences for protein folding and stability, and is a vital 
component of the manufacturing process as glycosylated proteins have lower immunogenicity and 
increased therapeutic efficacy and stability in the body. Such proteins may be referred to as 
glycoproteins, and constituted 12.5% (78 of 640) of all EMA approved drugs in 2012, the most 
common of all biologically-derived drugs (Kyriakopoulos and Kontoravdi, 2013). A large proportion of 
glycoproteins are therapeutic enzymes, which are administered as enzyme replacement therapies 
(ERT) to patients which lack or have low levels of specific enzymes. Another prominent category of 
glycoproteins are monoclonal antibodies (mAbs), which are used to bind to targeted cells or proteins 
in the human body in order to identify and/or destroy them, and are used in the treatment of cancer 
and autoimmune disorders. Glycoproteins have molecular weights ranging from about 30 kDa for 
erythropoietin (EPO), a cytokine which stimulates red blood cell production, to in excess of 100 kDa, 
with monoclonal antibodies having molecular weight of the order of about 150 kDa. 
The most complex biopharmaceutical products are those produced by viral propagation, with viral 
vectors for gene therapy of particular note. These treatments utilise relatively colossal molecules 
such as viral capsids, with the adeno-associated virus capsid having a molecular weight in excess of  
about 1 MDa. The mechanism of action of gene therapy differs from that of existing 
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biopharmaceutical treatments. Currently, many biopharmaceuticals are designed to replace or 
supplement substances in the body that are not naturally produced, often due to a defective or 
missing gene. As such, ongoing administration of manufactured versions of these substances is 
required to provide ongoing therapeutic benefit. In the case of gene therapy, the defective  or 
missing gene is replaced with a correctly functioning gene, allowing for the body to produce the 
previously absent substance over a longer, and potentially indefinite, period of time. The 
introduction of this correctly functioning gene is accomplished primarily through the use of viral 
vectors, viruses which have been modified to suppress possible pathogenic activity and transduce 
the target gene into the human body’s cells. This process is complex, and requires introduction of 
the gene to specific cells to ensure sufficient uptake to allow for prolonged production of the target 
substance. 
 
2.2.2 The biopharmaceuticals manufacturing process – current state 
 
Contemporary production of biopharmaceutical substances is accomplished through the use of 
large-volume stainless-steel vessels in which a cell culture ferments a growth medium to produce 
the target substance, often a protein or, in the case of certain vaccines or gene therapies, a virus. 
This substance is then separated from the cell supernatant in a series of purification stages 
employing variously: centrifugation, depth filtration, tangential flow filtration, homogenisation and 
chromatography to achieve high levels of purity and identity of the target substance. The majority of 
biopharmaceuticals are administered parenterally. To ensure patient safety, there is thus a 
requirement for microbiological controls including micro- and nanofiltration stages to remove 
pathogenic bacteria and viruses, while Water for Injection (WFI) is utilised for product and cleaning 
waters. Figure 1 shows an overview of a typical biopharmaceutical manufacturing process.  
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 Here: Figure 1: Overview of a typical biopharmaceutical manufacturing process, encompassing cell culture 
by fed-batch or perfusion; clarification of cell culture fluid by centrifugation, depth filtration and/or 
homogenisation; purification to drug substance by chromatography and tangential flow filtration, with 
added steps to inactivate and remove micro-organisms; and sterile filling of the drug substance to final drug 
product 
There are numerous options of cell lines which have been adapted for use in biopharmaceutical 
manufacture. Cell cultures often used include bacterial cultures such as E. coli, mammalian cultures 
such as Chinese hamster ovary (CHO), baby hamster kidney (BHK) and human embryonic kidney 293 
(HEK 293), plant cultures and insect cultures. The selection of cell culture is determined during 
process development and is influenced by the type of substance being produced. For example, 
glycoproteins are produced primarily by mammalian cell culture as mammalian cells can perform 
post-translational modifications similar to those provided by human cells (Kyriakopoulos and 
Kontoravdi, 2013). Proteins which do not require significant post-translational modification may be 
produced in bacterial or yeast cell cultures such as E. coli or S. cerevisiae which are simpler and more 
productive than mammalian cells. For the production of viral vectors for gene therapy, mammalian 
cell culture is most popular (Emmerling et al., 2016). The production of adenovirus and adeno-
associated virus is documented extensively in HEK 293 cell culture (Robert et al., 2017; Grieger et al., 
2016; Cortin et al., 2004; Chahal et al., 2014; Kamen and Henry, 2004) as the HEK 293 cell culture 
expresses certain proteins required for adenovirus and adeno-associated virus propagation.  
Cell culture fermentation is accomplished usually either on a fed-batch or perfusion basis. Fed-batch 
cell culture is composed of scale-up stages through a number of bioreactors of increasing volume 
until the culture reaches maximum cell density in the production bioreactor, the volume of which 
can exceed 40,000 litres. The cell culture is terminated prior to its death phase, and the bioreactor 
contents are harvested. In contrast, perfusion cell-culture operates at pseudo-steady-state. The cell 
culture is scaled up to an optimum cell density and inoculated in the production bioreactor. Fresh 
growth medium is added continuously, and cell culture fluid is harvested at the same rate. Cell 
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retention devices are utilised to maintain the cell density in the bioreactor, and constant cell bleeds 
may also utilised to prevent densities reaching unsustainable levels.  
Purification is carried out generally in a batchwise manner. Harvested cell culture fluid is clarified by 
centrifugation or depth filtration to remove cellular debris. If the target substance is produced 
intracellularly, as in the case of many bacterial cultures, homogenisation may be required to lyse 
cells and release the substance. Tangential flow filtration may be utilised to concentrate the cell 
culture fluid and exchange the depleted growth medium with purification buffers. Chromatography 
is then utilised, with three chromatography stages generally utilised: capture, intermediate and 
polishing. The target substance is separated from the cell culture fluid by charge (ion exchange), 
hydrophobicity or hydrophilicity (hydrophobic/hydrophilic interaction), affinity (immobilised metal 
or Protein A) or by size (size exclusion) to name but a few. The solution is treated to inactivate 
enveloped viruses which may be present, and tangential flow filtration is applied to exchange 
process buffers with drug formulation substance to stabilise substance for storage. The final solution 
may then be filtered to remove non-enveloped viruses and other micro-organisms prior to filling. 
3. Future trends in biopharmaceutical manufacture 
3.1 Fed-batch or perfusion? 
The choice of fed-batch or perfusion cell cultures under current manufacturing technology is 
typically a function of product stability and titre. Studies documented in the literature identify an 
association of extended cell culture residence times with impacts to glycosylation profile (Pacis et al., 
2011), heterogeneity (Liu et al., 2016) and on aggregation (Joshi et al., 2014), with the cause of these 
impacts linked to exposure of the product to specific enzyme activity within the cell culture . These 
can significantly impact critical quality attributes of the product such as biological activity and 
immunogenicity (Costa et al., 2012; Liu et al., 2016) and concomitant risks to therapeutic efficacy 
and patient safety. Monoclonal antibodies, which make up a significant portion of approved 
biopharmaceuticals (Walsh, 2014), are stable proteins, and can withstand extended durations under 
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the operating conditions of the bioreactor (Konstantinov, 2006). Thus, they are predominantly 
produced using the fed-batch cell culture mode, in which residence times may exceed 14 days. In 
contrast, many other recombinant glycoproteins are unstable, prone to formation of dimers or 
aggregates, and therefore must be produced in perfusion cell cultures to prevent degradation 
(Konstantinov, 2006; Meuwly et al., 2006). The residence time in perfusion cell culture mode is much 
shorter than fed-batch mode, with residence times exceeding 1 day unusual. In many cases, the 
target substance falls somewhere between these scenarios and the choice may be determined by 
factors such as established facility infrastructure (Konstantinov, 2006). Table 3 details a comparison 
of fed-batch and perfusion cell cultures. 
Table 3: Comparison of fed-batch and perfusion cell cultures 
Fed-batch culture Perfusion culture 
High protein/glycoprotein titres – >1 g/L 
Low viral genome titres – ~1x1012 vg/L 
Low protein/glycoprotein titres – 10-100 mg/L 
High viral genome titres – ~5x1012 vg/L  
Higher volumetric scalability Increased versatility 
Requires stable substances Higher cost-of-goods (growth medium dependent) 
Lag phase upon inoculation Consistent product quality 
Downstream bottlenecks  
  
For the production of viral vectors for gene therapy, the required viral genome (vg) titres for 
therapeutic dosage are documented for adenovirus and adeno-associated virus as being higher for 
perfusion systems over batch and fed-batch systems (Kamen and Henry, 2004; Cortin et al., 2004; 
Grieger et al., 2016). This is due to the “cell-density effect” (Kamen and Henry, 2004) whereby a limit 
in viral genome cell-specific production at high cell densities is reached due to growth medium 
limitations. This is analogous to challenges facing the adoption of perfusion technology for the 
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production of proteins and glycoproteins, however, interestingly, in this case the reduction in titre is 
instead observed in batch and fed-batch modes.  
Industry trends indicate a move toward the implementation of perfusion cell cultures, resulting from 
three main drivers: 
1. Increased product quality – operating at pseudo-steady-state contributes to improved 
product quality (Konstantinov, 2006; Meuwly et al., 2006). Additionally, significant portions 
of development drugs in pipelines are heavily glycosylated glycoproteins (Walsh, 2014), 
which may require a perfusion cell culture to maintain acceptable levels of product quality. 
 
2. Increased versatility – fed-batch cultures typically operate at levels exceeding 10,000 litres. 
Facing pressure from biosimilars, facilities which once produced large volumes of 
blockbuster drugs may now be retasked to produce multiple products. Similarly, the 
explosion of the orphan drugs market may warrant small -volume campaigns as opposed to 
lengthy production of single products. Implementing a perfusion cell culture may remove 
requirements for facility redesign and capital expenditure at the cost of reduced titres 
(Pohlscheidt et al., 2013). 
 
3. Lower volumetric requirements – the commercialisation of gene therapy providing indefinite 
therapeutic benefit from a single-dose may impact the volumetric production capacities 
required for treatment of even large patient populations. While initial uptake following 
approval may require large volumes, a drop-off is likely as no further dosages are required 
over long periods. This may impact the likelihood of any company constructing large -volume 
manufacturing facilities requiring large capital expenditures. Furthermore, with the potential 
for gene therapies to target existing conditions treated by proteins or glycoproteins on an 
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on-going basis, there is potential for large reduction in demand for existing treatments, 
making existing manufacturing strategies relying on large-volume production redundant. 
A number of studies document comparisons of fed-batch and perfusion cell cultures from an 
economic and product quality perspective (Meuwly et al ., 2006; Yang et al., 2014; Klutz et al., 2016). 
The outcome of these studies indicates higher productivity from fed-batch cultures (Meuwly et al., 
2006), while the application of perfusion cell cultures exhibits improved product quality (Yang et al 
2014). Fed-batch cell cultures proved more economically viable (Meuwly et al ., 2006; Klutz et al., 
2016). In order to achieve parity with fed-batch cultures, titres of perfusion cell cultures must 
improve to match those of fed-batch cultures, using a move known as “push-to-low” (Konstantinov, 
2006). The “push-to-low” method refers to the iterative reduction in perfusion rate, the rate at 
which fresh growth medium is supplied and harvested product removed. By reducing the perfusion 
rate, a greater residence time is achieved and increased utilisation of growth medium is seen, 
yielding higher titres of product. Barriers to reducing the perfusion rate include product stability 
under increasing residence times, the quality of growth medium, maximum cell density achievable 
and the capacity of the cell retention device implemented (Konstantinov et al ., 2006). 
 
3.2 Single-use technology 
Single-use technology has emerged as an alternative to contemporary stainless-steel manufacturing 
technologies. Composed primarily of plastics, single-use technology offers the prospect of flexible, 
multi-product facilities by elimination of the risk of product carry-over, which is of major regulatory 
concern (EudraLex, 2015). Additional benefits in the form of reduced capital costs and potential for 
debottlenecking during facility changeover make single-use technologies an attractive proposition 
(Shukla and Gottschalk, 2012). Table 4 describes the benefits and challenges of single-use 
technology. 
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Table 4: Single-Use Technology – Benefits and Challenges 
Benefits Challenges 
Elimination of CIP and SIP requirements Potential for leachables and extractables 
Reduced facility footprint Limited scalability 
Increased flexibility for changeover Increased supply-chain risk 
 Not fully realised for all unit operations 
Increased operating costs 
Single-use instrument calibration and reliability 
Increased potential for human error 
Robustness of materials of construction 
Potential increased contamination risk during 
perfusion campaign 
Increased/ongoing material consumption and waste 
disposal of non-recyclable single use equipment 
waste  
 
Challenges to the uptake of single-use technology include the risk to patient safety from potential 
leachables and extractables, the volumetric limit of about 2000L and the additional supply-chain risk 
due to the limited number of suppliers (Shukla and Gottschalk, 2012). A paucity of literature exists 
concerning the operation of perfusion cell cultures over long periods in single-use bioreactors, with a 
duration of 28 days documented by Klutz et al (2015), while periods of up to 200 days are utilised in 
the industry (Pohlscheidt et al., 2013). Extended operation of perfusion campaigns poses risks from 
contamination, due to additional operator interactions, and potential for increase in leachables and 
extractables due to exposure of the bioreactor container for extended periods at elevated 
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temperatures to the cell culture. While single-use technology is available for all unit operations, the 
capital costs associated with some equipment, such as TFF cassettes (~$10,000/m2) and 
chromatography resins (~$5000/L), limits any justification for the use of such equipment in a truly 
single-use fashion. Finally, utilising single-use technologies poses significant economic and 
environmental challenges due to the increased volumes of solid waste requiring disposal. Much of 
this is composed of plastics which are not readily recyclable, and so are removed to landfill or 
incineration at end of life, which poses sustainability challenges. 
 
3.3 Continuous Downstream Processing 
While continuous cell culture processing in the form of perfusion cell culture is well-established in 
the biopharmaceutical manufacturing sphere, continuous downstream purification processes are 
uncommon, with few documented in literature. While the current paradigm is for large, fed-batch 
cell cultures feeding similarly large batch purification trains, the previously mentioned economic 
risks to the industry from biosimilars and unsustainable treatment costs has led to a desire for 
increased volumetric productivity, reduced capital expenditures and an overall reduction in cost of 
goods (Klutz et al., 2015b). While single-use technology satisfies this in part, by reducing facility 
footprint and capital expenditures, it does not impact the issue of volumetric productivity (Klutz et 
al., 2015b). As a result, the adoption of continuous manufacturing becomes attractive. This can be 
accomplished by employing perfusion cell culture in tandem with continuous purification unit 
operations such as tangential flow filtration and chromatography. Fully continuous processes have 
been documented in the literature (Klutz et al., 2015a; Klutz et al., 2015b; Walther et al., 2015) and 
continuous chromatography operation also has been documented (Steinebach et al., 2016).  Table 5 
describes the benefits and challenges of implementing continuous purification.  
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Table 5: Continuous downstream purification: benefits and challenges 
Benefits Challenges 
Increased volumetric productivity Potential economic benefits may 
not be realised 
Increased separation efficiencies Regulatory challenges from 
product licence changes 
Increased product quality Development of reliable methods 
for all unit operations 
Reduced capital expenditures Increased complexity 
Debottlenecking the process 
 
Continuous purification processing is plausible utilising current technologies (Jungbauer, 2013). 
Significant challenges exist to its implementation at a commercial scale, ranging from technical 
issues including the development of a reliable method of incubation for steps such as viral 
inactivation and diafiltration (Przybycien and Titchener-Hooker, 2015) to uncertainties surrounding 
the predicted economic benefits being realised at commercial scale (Jungbauer, 2013) and, perhaps 
most significantly, the regulatory requirements to change product registrations (Przybycien and 
Titchener-Hooker, 2015). Until commercial scale applications of continuous purification processing 
are implemented and analysed, its development and uptake may remain inhibited by established 
attitudes within the industry. 
3.4 Drug discovery and optimisation 
From a new drug discovery perspective, of particular promise is gene therapy, the first of which 
obtained approval by FDA in 2017 following an estimated 1,992 gene therapy clinical trials 
worldwide in the period 1989-2013 (Walsh, 2014). While gene therapies offer breakthrough 
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treatments, they may be beset by economic issues, as noted in previous sections, and by previous 
challenges to patient safety, which culminated in the death of a patient during clinical research in 
1999 (Wirth et al, 2013) and which stymied efforts to implement the technology. It remains to be 
seen whether gene therapies can be realised on a grand scale. 
For existing drugs, challenges exist from therapeutic efficacy and the rise of biosimilars. Currently, 
many approved drugs require significant doses (>1 mg/kg) to deliver therapeutic effects, resulting in 
patients requiring annual doses in gram-quantities (Love et al., 2013). Potency and efficacy of these 
drugs is affected by variations in glycosylation profile, heterogeneity and aggregation (Costa et al ., 
2012; Liu et al., 2016) which contribute to the necessity for high dosages to be delivered. 
Improvement of the therapeutic efficacy by increased uniformity of product and concomitant 
reduction in required therapeutic dosage is essential to enable greater access and reduction in price 
of established products (Love et al., 2013). The challenge of this may be solved by increasing process 
understanding from current manufacturing processes, or by discovery and approval of biosimilars 
exhibiting greater therapeutic benefit. These needs may place pressure on companies to improve 
current approved products, or face competition from biosimilars wi th lower-costs and/or improved 
therapeutic benefits. 
In summary, the future of biopharmaceuticals manufacturing is tending towards small -volume, high-
potency treatments produced in flexible, multi-product facilities utilising continuous manufacturing 
and single-use technologies, as illustrated in Figure 2.  
Here: Figure 2: Overall trend in biopharmaceutical research and innovation indicating a move towards high-
potency, novel treatments; production using single-use technology; and realisation of continuous 
manufacturing throughout the manufacturing process  
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4. Sustainability considerations and research in the biopharmaceutical industry 
4.1 Reflections on sustainability for the biopharmaceutical industry 
It has been suggested that sustainability, as a concept, entails facilitating the potential for life to 
flourish on this planet over a prolonged period of time, that is, for many generations to come 
(Ehrenfeld, 2009). While there are many ways of representing sustainability, the concentric model 
shown in Figure 3 reminds us that economic activity is embedded within human society, which in 
turn exists within the parameters of the physical environment.  
Here: Figure 3: Concentric circle model of sustainability which shows the economy existing within society, 
which exists within the environment (Adapted from Lozano, 2008) 
One of the key aspects of sustainability thinking is to enable an “integrational perspective” (Lozano, 
2008) or an “integrative approach” (Hedlund-de Witt, 2013, 2014; Byrne, 2016); that is, one which 
recognises the influence and impact of disparate (though ultimately interconnected) elements 
within the operation of a larger complex system. Under the prevailing market-based socio-economic 
paradigm that shapes our world, microeconomic benefit-risk evaluation is the usually singular factor 
in decision-making (with the question of how and to whom the benefits and risks are allocated being 
a contested matter). Frequently, therefore, the societal and environmental impacts of human 
activities are absent from decision-making or represent marginal considerations compared to those 
of investors’ financial “bottom line”. The consequences of ‘business-as-usual’ economic practices 
have been sharply highlighted at the time of writing by reports on the pace and implications of 
climate change (IPCC, 2018); the extraordinary loss of biodiversity (WWF, 2018); and on emerging 
threats to global freshwater availability (Rodell et al., 2018).  Consequentially, given increasing 
recognition of such existential threats, many businesses are now seriously examining their 
production systems in order to minimise environmental damage arising from their practices.  
How, then, can sustainability thinking make itself felt in biopharmaceuticals manufacturing? By their 
very nature, biopharmaceuticals are intended to bring about improved quality of life and life 
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expectancy, often for debilitating diseases in vulnerable patients such as children. However, many 
existing business and scientific practices within the pharmaceutical industry as a whole, and 
including the biopharmaceutical sector, have served to degrade the environment and erode public 
trust in pursuit of profitability. There are a number of examples of such practices, some of them 
deliberate, others a consequence of unforeseen outcomes. For example, the increase in 
pharmaceutical uptake and subsequent excretion by patients to wastewater has resulted in 
unintended consequences for the aquatic environment through disruption of biological processes 
resulting in damage to some aquatic species (Fabbri, 2014). Additionally, pharmaceutical effluents 
have been implicated in the development and proliferation of antimicrobial-resistant strains of 
micro-organisms (Milmo, 2017). A key obstacle to proposed remedies of the latter practice is the 
additional costs associated with achieving environmentally benign manufacturing processes, which 
could impact access to generic forms of established drugs, particularly antibiotics (Milmo, 2017). 
Pharmaceutical pricing is a universal problem with impacts on access across high-income and low-
income countries alike (Hurst, 2017). Accusations of price-gouging are rife, with the case of Turing 
Pharmaceuticals’ 5000% increase in pricing of pyrimethamine (Daraprim; Turing Pharmaceuticals, 
2017) making headlines worldwide due to the apparently exploitative practices it embodied (Saltiel 
and Finnefrock, 2018). While there may be a variety of reasons for pharmaceutical pricing, such as 
market size, recoup of development costs and supply chain problems, the conflation of any and all 
pricing strategies with more infamous examples has led to a reduction in public trust in 
pharmaceutical producers applying fair costs on their products. Furthermore, transparency 
regarding the treatments provided by pharmaceutical companies is controversial, with suggestions 
by some authors that clinical trial details are often published only if positive, accusations that clinical 
trial data published has been cherry-picked to strengthen arguments for approval, and that patient 
safety is compromised by a lack of public availability of regulatory hearings, investigations and 
approvals (Löfstedt and Way, 2016). From an environmental perspective, growth in the number and 
volume of biopharmaceuticals requiring manufacturing and transport globally increases the cradle-
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to-grave impact through increased emissions to land, air and water and greater usage of natural 
resources. The aforementioned issues combine to impair the sustainability of the pharmaceutical 
sector as a whole, driven by environmental degradation and poor socio-economic relationships, the 
former of which leads to the destruction of the natural ecosystem humanity relies on to survive and 
thrive, and the latter of which corrodes societal trust and reduces and removes safe, equitable 
access to treatment worldwide.  
Away from nefarious practices, the “business-as-usual” approach to biopharmaceutical innovation 
and manufacture also contribute to increased sectoral fragility. The rate of approval of 
biopharmaceuticals has maintained a constant trajectory since the approval of Humulin in 1982, 
with FDA approvals in 2017 reaching a near-record high (DeFrancesco, 2017). While each approval is 
a milestone in the treatment of disease, there are corresponding impacts to the environment and 
society. As previously discussed, the financial success of biopharmaceutical manufacturers is 
contingent on strong pipelines and gaining regulatory approval for new products on a consistent 
basis (Thakor et al., 2017). This has resulted in spiralling development costs at greater than the rate 
of inflation (DiMasi et al., 2016) and resultant increased pricing to recoup these costs, requiring 
greater investment from governments and impinging on access to treatments.  
Overall, in order to promote a more sustainable sectoral model, the manifestation and application of 
sustainability thinking (economically, socially, environmentally and ethically) in the 
biopharmaceuticals manufacturing sphere is required to address the socio-economic and ethical-
environmental challenges posed by contemporary manufacturing, innovation and economic 
philosophies in order to develop and deliver accessible treatments to those afflicted by disease 
globally. 
4.2 Established research 
Research in the area of biopharmaceuticals regarding the environmental impacts resulting from their 
manufacture is not well-documented, as is evidenced by scant coverage of this in the literature. 
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Pollock et al. (2013) compared fed-batch and perfusion cell culture processes under environmental 
uncertainty, determining that the fed-batch cell culture scenario performed better from an 
environmental perspective as a result of reduced water consumption and consumable usage.  
Pietrzykowski et al. (2015) conducted a detailed life cycle assessment of the production by fed-batch 
cell culture of a monoclonal antibody under single-use and conventional stainless-steel modes of 
operation. The result of this analysis indicated reduced environmental burden from the single-use 
process across a variety of operating scales due to the reduced need for water and steam utilities 
associated with the elimination of cleaning and sterilisation procedures, which outweighed the 
increased solid waste disposal requirements associated with the increased use of single-use 
technologies. Bunnak et al. (2016) performed a life cycle assessment of the production of a 
monoclonal antibody under fed-batch and perfusion modes of operation, drawing the conclusion 
that the fed-batch process was more environmentally friendly when the perfusion process pooling 
duration, the interval at which harvested material was combined and sent for purification, was four 
days, but became less environmentally friendly when extended to eight days. Finally, Conley et al. 
(2017) conducted an evaluation of eco-friendly detergents for enveloped virus inactivation. Triton X-
100 is used by many biopharmaceuticals manufacturers in conjunction with an organic solvent to 
inactivate enveloped viruses by disrupting their lipid membranes and rendering them inert. Triton X-
100 may degrade to an alkylphenol upon discharge to aquatic environments, with resultant impacts 
as an endocrine disruptor on aquatic species and the wider environment. Conley et al. (2017) 
conducted a study to determine whether an eco-friendly detergent could be implemented to replace 
Triton X-100, and determined that lauryldimethylamine-N-oxide (LDAO) could be substituted for 
Triton X-100 due to its comparative ability to inactivate enveloped viruses and low ecotoxicity. While 
this was not a quantitative study as per Bunnak et al . (2016) or Pietrzykowski et al. (2015), it is 
noteworthy due to its potential to eliminate toxic substances from the biopharmaceutical 
manufacturing process. 
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To summarise, the major conclusions stemming from the established research in the area indicate 
that fed-batch cell culture processes have reduced environmental impacts than perfusion cell culture 
processes (under certain conditions), primarily due to the increased water consumption associated 
with perfusion cell cultures, and also that single-use technologies are more environmentally benign 
than conventional stainless steel, with the increased solid waste generated offset by a reduction in 
energy usage associated with cleaning and sterilisation processes. Additionally, consideration for 
eliminating toxic substances has been documented, in the case of a particularly hazardous substance 
(Triton X-100), however investigation of other pollutants is not present in the literature. 
5. Next steps for sustainability thinking in the biopharmaceutical industry 
While established research in the area provides some conclusions with regard to the environmental 
implications of biopharmaceutical manufacture under diverse modes, there is scant research 
informing stakeholders of the preferable manufacturing modes from an integrated perspective 
incorporating the three core facets of sustainability thinking: economy, society and the environment. 
By contrast, investment decisions in biopharmaceutical production are to date guided almost 
exclusively across the industry by financial cost benefit analysis and do not even take into account 
broader environmental issues such as around water or material consumption. As described by 
Ramasamy et al. (2015), there does not exist a decision-making framework within the 
biopharmaceutical industry which incorporates environmental concerns, with few life cycle 
assessment studies completed for the biopharmaceutical industry in comparison to industries such 
as the energy sector for which more than five hundred exist. From a societal viewpoint, impacts 
from the biopharmaceutical manufacturing life-cycle have not yet been comprehensively 
documented, but rather tackled on a piece-meal basis through the use of process-level tools such as 
life-cycle costing for economic sustainability (Bunnak et al ., 2016) and at patient level, through well-
documented concerns over drug pricing and availability (Love et al., 2013; Garattini and Padula, 
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2018). It is clear, then, that integrated, system-wide evaluation is required to determine the impact 
of biopharmaceutical manufacture from an integrative sustainability viewpoint. 
Of interest for this evaluation are industrial ecology models proposed by Allenby and Graedel 
(Allenby and Graedel, 2010). Industrial ecology is defined as the study of material and energy flows 
through industrial systems, and can be understood as the interaction between the biosphere, the 
environment on which all life depends to survive, and the technosphere, the sphere of technological 
development on which humanity depends to transform raw materials from the biosphere into useful 
goods and services, with concomitant wastes released to the biosphere as a result. Modelling of the 
relationship through an industrial ecology lens may be achieved through use of the following 
(Allenby and Graedel, 2010): 
 Class 1 model - Model incorporating the technological, environmental or human aspect 
singularly (Examples include economic evaluations, process modelling and environmental 
impact assessments). 
 Class 2 model - Model incorporating two of the technological, environmental or human 
aspects (Examples include life cycle assessment, life cycle costing and eco-design). 
 Class 3 model - Model incorporating technological, environmental and human aspects in a 
holistic fashion 
The endeavour of developing a Class 3 model for biopharmaceutical manufacture could be pursued 
to determine the cradle-to-grave impacts holistically, beginning with the following: 
 Further documentation of the environmental impacts of diverse modes of operation 
including perfusion and fed-batch cell cultures, batch and continuous purification, and 
single-use and conventional technologies, and possible applications of design-for-
environment principles 
 Evaluation of the trends in biopharmaceutical manufacture and development of holistic 
decision-making tools incorporating the environmental and societal aspects of manufacture, 
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along with the technological and microeconomic considerations which currently govern 
decision-making 
 Identification and prioritisation of the development of novel technologies with potential to 
ameliorate the environmental impacts of biopharmaceutical manufacture 
 Continued macroeconomic assessment of biopharmaceutical manufacture, approval and 
sale and incorporation of technological and environmental models within these assessments  
Here: Figure 4: A vision of sustainable biopharmaceutical manufacture, achieved by embracing sustainability 
principles in the technological, environmental and societal paradigms.  
Figure 4 is intended to show a sustainable vision of biopharmaceuticals manufacture, driven by 
technological, environmental and societal consideration and innovation of the product lifecycle, 
from discovery through manufacture to the patient level. Initially, the development of new drugs 
and optimisation of existing drugs to achieve equitable or superior therapeutic benefits under lower 
dosages is important to reduce volumes of drugs required to be manufactured, with positive impacts 
on environmental emissions and operational expenditures as a result. Additionally, the pursuit of 
novel therapeutics such as gene therapies with potential for single doses providing life-changing 
results could also yield environmental benefits, potential for adverse societal impacts (such as those 
described by Brennan and Wilson (2014)) notwithstanding. 
Continuing through the product life-cycle, the manufacturing processes utilised require exploration 
and assessment to inform decision-making. Under current regulatory framework, changes to 
product registrations incur additional time and expense of the regulator and the manufacturer, and 
are generally only made if absolutely necessary. Therefore, it is important that consideration of 
environmental and societal impacts is made prior to regulatory submissions and capital expenditure. 
To this end, the documentation of life-cycle assessment and life-cycle costing must be completed to 
develop an economic and environmental framework that can inform decision-making at the earliest 
possible stages of the product life-cycle. Additionally, novel amelioration technologies may influence 
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manufacturing processes through discovery and development of environmentally and economically 
superior technologies. 
Finally, at a socioeconomic level, several topics require attention. From a microeconomic 
perspective, a more transparent life-cycle costing of drug discovery and manufacture should be 
provided. Current estimates of the cost of drug discovery fluctuate wildly, while cost of drug 
development has increased above the level of inflation (DiMasi et al ., 2016). The cost of 
manufacture can often be a relatively minor part of drug pricing, which may render any economic 
gains in the manufacturing process of negligible benefit to the end user. Increased transparency in 
this area would enable health authorities to understand the primary costs associated with each 
treatment and could lead to positive-regulating of certain technologies, in order to prevent excessive 
treatment costs. 
A more holistic approach taken by drugs manufacturers could also involve more explicit support for 
reducing drug requirements societally through, for example, supporting the development of public 
health initiatives such as cycle to work greenways and public recreational spaces, as well as policy 
measures to promote healthy eating, etc.  
Macroeconomically speaking, the provision of biopharmaceuticals for treatment of all manner of 
illnesses is widely-documented and can be the source of dispute globally. Accusations of price -
gouging are often levied at biopharmaceutical manufacturers, and the price of biopharmaceuticals 
has been documented as 20 times higher on average compared to small -molecule treatments 
(Walsh, 2014). Pressure is thus placed on governments to provide treatments to its citizens in a 
prudent manner, while remaining often at the mercy of drug manufacturers, a combination which 
can result in inequalities of access. While there is no easy remedy to this situation, the continued 
development of informed policies incorporating the product life-cycle costs, including the 
environmental costs, in addition to increased transparency of drug pricing, will lead to maximisation 
of drug access. 
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6. Conclusions 
Biopharmaceuticals continue to gain approval in significant numbers, and provide real societal 
benefit from treatment of hitherto untreated illnesses and malaises. The advent of breakthrough 
gene therapies could herald the dawn of a golden age in biopharmaceutical development, yet the 
risks posed from historical economic difficulties, competition from biosimilars and accusations of 
unfair pricing may cause turbulence in the coming years. On a larger scale, humanity faces 
challenges from ecosystem degradation, anthropogenic climate change and rising levels of economic 
inequality. Sustainability principles can be applied to the biopharmaceutical industry in order to 
understand the overall impact of biopharmaceuticals manufacturing on the economy, soci ety and 
environment, and to facilitate meaningful continued contributions to human flourishing. 
Trends in the biopharmaceutical industry indicate a move towards fully continuous manufacturing 
processes utilising single-use technologies to produce multiple high-potency treatments in flexible 
manufacturing facilities. Challenges existing to this vision include economic feasibility concerns over 
single-use technologies and continuous manufacturing, scientific challenges from product quality 
and societal apprehension over existing product availability and new product pricing.  
Established research in the area indicates environmental benefits from utilisation of fed-batch cell 
culture in tandem with single-use technology; however, limited information is available, providing 
minimal direction to policy- and decision-makers in the way of environmentally benign 
manufacturing routes. Similarly, macroeconomic policies such as inequality of access and unfair 
pricing are examined in isolation from the technological and environmental aspects of product 
manufacture. Integrated perspectives are required to analyse sustainability of existing practices and 
identify areas for improvement. One such method proposed is the application of industrial ecology 
models to the biopharmaceutical manufacturing life-cycle, in an effort to ensure continued 
innovation, reduced emissions to air, land and water, fair, equal access to biopharmaceutical 
treatments over the coming generations, and ultimately, human flourishing.  
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